Latest Research Collaboration News

Racura Oncology has raised $34.3 million through shareholder-backed initiatives, securing funding for its lead asset RC220’s clinical trials in AML, EGFRm lung cancer, and cardioprotection in solid tumour patients.

Echo IQ has partnered with Mayo Clinic to assess its AI platform's ability to predict heart failure risk in patients undergoing cancer therapy, targeting the growing cardio-oncology sector.

Control Bionics advances its neural-signal technology across assistive communication, sports, and medical sectors, securing key US reimbursement and distribution agreements while broadening its international footprint.

Simble Solutions has launched a strategic collaboration with Macquarie University to accelerate development of its exclusive zinc oxide nanosensor technology, targeting e-skin applications and integration into its IoT platforms.

FirstWave Cloud Technology posted a cash-flow positive Q3 FY26 with a 125% jump in customer receipts and locked in landmark contracts with Banobras and Services Australia, underpinning its AI-driven compliance strategy.

Pure Resources has completed a pivotal sampling program at Garnet Hill, securing over 100 kg of material to underpin its multi-stream US defence materials platform, targeting abrasive garnet, jumbo flake graphite, and rare earth recovery.

FirstWave Cloud Technology delivered a strong Q3 FY26 with a $1.40m net operating cash inflow and a major two-year licensing agreement with Mexico’s Banobras bank, marking a key milestone in its AI compliance pivot.

Pure Resources has demonstrated that its Carbon Nanotube Fibre (CNTF) achieves thermal conductivity up to 600 W/m·K, outperforming copper by 1.5 times and aluminium by up to 3 times, positioning it as a breakthrough for AI, defence, and high-power electronics cooling.

Nexsen Limited teams with Universiti Malaya to launch a joint research facility aiming to develop a rapid biosensor detecting E. coli and Salmonella simultaneously, addressing a critical food safety gap in Southeast Asia.

4DMedical has made significant strides in commercial adoption of its CT:VQ™ lung imaging technology, securing top US hospital contracts, regulatory approvals in Europe and the UK, and a major pharmaceutical partnership, all backed by strong capital raises and inclusion in the S&P/ASX 200.

Percheron Therapeutics has secured $2.2 million through an entitlement offer to fund the next stage of its HMBD-002 oncology program, with manufacturing underway and key data presentations lined up at major cancer conferences.

Starpharma has confirmed FDA alignment for its DEP® HER2 first-in-human phase 1 trial, with preparations underway for a mid-2026 start. The biotech also progressed strategic partnerships, published promising data with Genentech, and reported a $14.1 million cash balance alongside rising Viraleze™ sales.